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ABSTRACT 
 
 Vaccinations provide protection against deadly diseases and children are 
scheduled to receive many immunization injections before the age of six. However, 
painful procedures, such as immunizations cause negative short- and long-term 
consequences for children. The Gate Control Theory of Pain suggests that physical 
interventions may be helpful, but they have not yet been validated as an effective 
intervention to manage children’s acute pain. This randomized trial examined the 
effectiveness of the ShotBlocker®, a physical intervention designed to decrease 
children’s injection pain, in a sample of 89 4- to 12- year-old children receiving 
immunizations at a pediatric practice. An ANOVA revealed no significant effect of 
treatment group (Typical Care Control, Placebo, and ShotBlocker®) on any measure of 
child distress. Clinical and theoretical implications are discussed. 
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INTRODUCTION 
Childhood immunizations are a priority for public health officials because the 
vaccinations benefit the child and the public – children are inoculated against fatal 
illnesses and the public is protected from the spread of diseases. According to the Center 
for Disease Control and Prevention (CDC), children should receive approximately 28 
inoculation injections before they are six years old (CDC, 2004). These routine and brief 
procedures provide protection against many infectious diseases, such as, polio, measles, 
diphtheria, whooping cough, rubella, and mumps. 
Intramuscular immunizations are typically administered via a needle, which 
pierces the epidermis, dermis, and subcutaneous layers of the skin, and the vaccination 
medication is injected into the muscle tissue. Unfortunately, this procedure results in 
short- and long-term negative repercussions for the pediatric patient. The immediate 
impact is high levels of fear and anxiety spanning the whole medical visit and intense 
pain during and briefly following the immunization injection itself. Jacobson, Swan, 
Adegbenro, Ludington, Wollan, & Poland (2001) found that 45% of 4- to 6-year-old 
children in their sample showed signs of high distress during vaccinations. The fear of the 
injection can cause time-consuming struggles between the patients and the office staff 
(Reis & Holubkov, 1997), and often physical restraint of the child is required to perform 
the procedure (Fanurik, Koh, Schmitz, & Brown, 1997).  
Immunization distress also results in negative long-term outcomes. Children who 
experience high levels of anxiety and pain during an immunization are more likely to 
have elevated distress levels for subsequent injections (Fanurik et. al., 1997; Fowler-
Kerry & Lander, 1987). The distress of the child might interfere with parent compliance 
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in bringing the child in for future immunizations, and also might result in physicians 
withholding subsequent injections during that same visit, thus, increasing the disease risk 
for that child and others who come in contact with that child (Madlon-Kay & Harper, 
1994; Meyerhoff, Weniger, & Jacobs, 2001; Reis, Jacobson, Tarbell, & Weniger, 1998). 
It is also possible that early painful experiences result in physiological changes, leading 
to elevated pain responses during later procedures (Taddio, Goldbach, Ipp, Stevens, & 
Koren, 1995). This is thought to be especially true for premature infants, because the 
stage of pain receptor neuronal development is particularly vulnerable to detrimental 
long-term effects (Young, 2005). Along these lines, a retrospective study found that 
adolescents born prematurely had higher pain sensitivity then their full term peers 
(Busilka, Nuemann, Zmora, Feldman, & Bolotin, 2003). 
In addition, early negative immunization experiences might contribute to 
avoidance of health care as adults, as well as fear, anxiety, pain, and ineffective coping 
strategies in adulthood (Pate, Blount, Cohen, & Smith, 1996). Beyond fear and anxiety, 
Hobbie et al., (2000) found needle pain associated with treatment is correlated with Post 
Traumatic Stress Disorder symptoms in childhood cancer survivors. Considering there 
are multiple negative short- and long-term outcomes associated with children’s 
vaccination pain, it is important to fully understand theories of pain, how pain is assessed 
in children, and what pain management treatments are available. 
Theory of Pain 
In the 17th Century, the prevailing explanation of pain was the Specificity Theory 
of pain. This theory proposed that pain impulses traveled directly to the brain; hence, the 
experience of pain would be directly and linearly related to the injury. In other words, 
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pain would be proportional to the extent of physical damage done to body tissue. This 
theory left little room for psychological factors in the experience of pain and greatly 
influenced how pain was diagnosed, conceptualized, and treated. 
In 1965, Melzack and Wall introduced the Gate Control Theory of pain, which is 
still the dominant theory accepted today (Melzack & Wall, 1965). The Gate Control 
Theory provides a multi-dimensional understanding of the complex phenomenon of pain 
and its multiple influences. Melzack and Wall proposed that the pain signal is transmitted 
from the peripheral nervous system to the central nervous system. In the central nervous 
system the signal is modulated by a gating system in the dorsal horn of the spinal cord 
before it reaches the brain; thus, the pain perception can be increased or decreased 
depending on influences on the gating system. There are two proposed means of 
impacting the gating mechanism. First, descending nerve impulses from the brain can 
interfere with the ascending pain signal from the tissue damage. These signals from the 
brain might include cognitive or emotional factors, such as thoughts, beliefs, emotions, 
mood, prior experience, expectations, memories, attention, and cultural attitudes. For 
example, memories of a prior negative experience or anxiety might heighten pain 
experience, whereas a positive mood or pleasant distraction might decrease the pain.  
The second mechanism influences pain perception through ascending signals 
from the peripheral nerves, which function as competing sensory information. There are 
two types of nerve fibers that carry the majority of pain signals to the spinal cord: small 
diameter myelinated and unmyelinated (A-delta) fibers and large diameter myelinated 
(A-beta) fibers. Physical stimulation such as rubbing, massage, and vibration cause 
excitation in the A-beta nerve fibers, which conduct the signal more quickly than the A-
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delta fibers, where pain due to tissue injury is transmitted. If a pain signal is traveling to 
the brain via the A-delta fibers and a simultaneous physical stimulation signal is sent via 
A-beta fiber, the physical stimulation signal will reach the brain first because they 
moving more quickly then the pain signal. According to the Gate Control Theory, the 
pain perception will be diminished via interference by the other physical stimulation. 
Given this complex theory of pain, assessment of pain typically involves a 
comprehensive battery. 
Assessment of Children’s Pain 
Current views of pain are that it is a multidimensional experience, defined by the 
International Association for the Study of Pain (IASP) as a negative physical and 
emotional experience caused by actual or potential tissue damage. IASP also 
acknowledges that pain is subjective and that, although it is certainly a bodily sensation, 
it is also an unpleasant emotional experience (Merskey & Bogduk, 1994); therefore, 
assessing children’s pain requires a multi-method approach (McGrath, 1987). Child’s 
self-report, observer’s (e.g., parent, nurse) ratings, behavioral measures, and 
physiological measures are commonly used to assess children’s pain. 
Child Self-Report 
 As the Gate Control Theory details, a number of pain factors are personal, 
internal, and subjective; therefore, self-report is critical to pain assessment in children 
(Finley & McGrath, 1998; McGrath, 1987). A variety of self-report measures have been 
developed to measure children’s pain including verbal ordinal scales, graphic rating 
scales, visual analog scales, and pictorial scales. Facial expression scales have 
advantages. They are developmentally appropriate for younger children because they 
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make minimal cognitive demands, are not dependent on reading skills, and typically 
represent a continuum of the universal response to pain (Champion, Goodenough, von 
Baeyer, & Thomas, 1998).  
Some pictorial scales, such as the Oucher Scale (Beyer, 1984), use photographs of 
children, but most rely on cartoon depictions. It is possible that children may be 
distracted by age, gender, and race in photographs, which is an advantage of simple 
cartoon graphics (Champion et al., 1998). One consideration is the depiction of emotion 
in the image. Some scales use a smiling face for an anchor and a crying face with tears on 
the distressed end of the continuum, which might influence ratings (e.g., if the child is not 
crying, the child might not select the face with tears; Chambers & Craig, 1998). To 
remedy this problem, some scales assess emotion (e.g., anxiety) separately, such as the 
Children’s Anxiety and Pain Scale (Kuttner & LePage, 1989). One of the most widely 
used and validated child ratings scale of pain is the Faces Pain Scale – Revised (FPS-R; 
Hicks, von Baeyer, Spafford, van Korlaar, & Goodenough, 2001), which consists of six 
cartoon faces expressing no pain to extreme pain. 
Observer Report 
 Parents’ and medical staffs’ perceptions of children’s pain are often the deciding 
factor in whether or not pain management treatment will be employed (Manne, Jacobsen, 
& Redd, 1992). For this reason, it is important to assess how they rate the pain experience 
of the child. Another advantage is that observer report provides another source and 
possibly assesses a different aspect of the child’s experience (Manne et al.). Observer 
ratings are typically done via questionnaires, likert-type ratings, and visual analog scales 
(Blount et al., 1997). These types of measures are also useful for assessing parents’ and 
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health care providers’ own anxiety or other perceptions (e.g., child coping; effectiveness 
of intervention) concerning the procedure (Cohen, Blount, & Panopoulos, 1997). 
Physiological Measures 
Physiological measures such as blood pressure, heart rate, respiratory rate, and 
palmar sweat index are used to measure pain and overall distress in pediatric patients 
(Blount, Piira, & Cohen, 2003; McGrath, 1987). Although the use of these physiological 
measures is common in pain research, there is question as to whether they are actually 
measuring pain. For example, physiological responses can be caused by another number 
of factors, such as emotional state, movement, or room temperature (Blount et al.; Sweet 
& McGrath, 1998). Some research has supported the use of heart rate as a physiological 
measure of pain, showing decreased heart rate when analgesics were administered and 
decreased heart rate as a result of behavioral interventions. On the other hand, 
physiological measures may potentially influence anxiety and pain in children if they are 
invasive and produce discomfort. In addition, measures are not always practical in a 
clinical setting because they are costly and time consuming (Blount et al; Sweet & 
McGrath). Although none of the physiological measures are ideal measures of pain, heart 
rate is promising because of its ease of use and non-invasive nature (Sweet & McGrath). 
Observational Measures 
Researchers sometimes use measures of observed behaviors in procedural pain 
because children’s overt behaviors serve as the first indicator of pain and they are less 
susceptible to bias than subjective reports. The child’s pain behavior may influence both 
the child’s perception and evaluation of the painful experience. Observational measures 
are also important because the child’s behavior influences their social environment 
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(McGrath, 1998). The challenge with observational measures is that coding can be a time 
consuming process that requires many hours of work from well-trained coders.  For this 
reason, observational coding is not consistently used in pain research. 
Many observational measures have been developed for use with children 
undergoing painful medical procedures, such as the Procedural Behavior Rating Scale 
(PBRS; Katz, Kellerman, & Siegel, 1980), Observational Scale of Behavioral Distress 
(OSBD; Elliott, Jay, & Woody, 1987), Child-Adult Medical Procedure Interaction Scale 
(CAMPIS; Blount et al. 1989), and the Children’s Hospital of Eastern Ontario Pain Scale 
(CHEOPS; McGrath, 1998). Scales such as these typically quantify discrete behaviors 
associated with child pain, such as crying, facial changes, verbal communication, 
screaming, grimacing, or flailing. Regardless of the modality of the measurement, 
assessment tools are invaluable to health care professionals in quantifying pain and 
guiding the initiation and termination of pain management interventions. 
Overview of Pediatric Pain Management Strategies 
Researchers and clinicians have evaluated various pain management techniques. 
In general, pain management approaches can be categorized as pharmacological, 
behavioral, and physical. Pharmacological treatments to reduce procedural pain include 
medications for sedation and the numbing of pain with and without consciousness. 
Medical complications are possible, and use of the medications usually requires the 
presence of personnel with advanced training to handle any possible medical 
complications. A popular topical anesthetic is Eutectic Mixture of Local Anesthetics 
(EMLA®), which is a cream composed of lidocaine and prilocaine. Studies on the 
effectiveness of EMLA® are mixed with some finding it to reduce pain during injections 
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(Cassidy, et al., 2001) and others finding no benefit (Cohen, 2002; Cohen, Blount, Cohen, 
Schaen, & Zaff, 1999). A drawback of EMLA® is the delayed onset of the anesthesia 
effect (60 min) and cost (Reis & Holubkov, 1997; Reis, Jacobson, Tarbell, & Wenieger, 
1998). An alternate pharmacological approach is cold spray, which provides a fast acting 
numbing of the skin. Ethyl chloride and fluoromethane sprays are applied 15 seconds 
before the injection and have been shown to be as effective as EMLA® (Reis & 
Holubkov). Unfortunately, some children do not like the sensation or are scared by the 
spraying sound (Reis & Holubkov), and some studies have indicated that these sprays are 
not tolerated well by small children (Zappa & Nabors, 1992). 
There are practical limitations to pharmacological pain management, such as the 
time delay, expense, and need for additional medical professional to be present. It is also 
important to note that pharmacological treatments do not typically treat children’s pre-
procedural anxiety or address other psychological factors that might impact the intensity 
of the pain. 
Several behavioral strategies have been validated (for a review, see Powers, 
1999). Common psychological interventions include relaxation training, distraction, 
guided imagery, hypnosis, and modeling (Blount et al., 2003; Fanurik, Koh, Schmitz, & 
Brown, 1997; Piira, Goodenough, & von Baeyer, 2002). The Gate Control Theory 
suggests that these interventions primarily work by activating descending signals from 
the brain that interfere and suppress the pain signal. In contrast to pharmacological 
interventions, there are no negative side effects and these approaches help to reduce both 
pre-procedural anxiety and procedural pain and anxiety. These techniques usually involve 
the mastery of a new skill to help cope with a stressful situation. However, training to 
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develop these skills can be time consuming and costly, making some behavioral 
interventions difficult to implement in clinical settings (Cohen, Blount, & Panopoulos, 
1997).  
The third category of pain management techniques is physical interventions, 
which involve direct stimulation of the area near the noxious stimulus. These treatments, 
such as massage, touching, or rubbing of the tissue, are theorized to travel via the faster 
A-beta fibers and interfere with the other ascending pain signal, which is transmitted on 
the slower A-delta fibers. This helps explain of why people commonly rub or squeeze a 
part of the body immediately after an acute injury.  
A classic example of a physical pain intervention is acupuncture, an Eastern 
medical practice first used over 2,000 years ago (Parris & Smith, 2003). Acupuncture 
involves very fine needles inserted into the skin on specific areas of the body. The 
needles are theorized to stimulate the energy flow and restore energy balance in the body. 
On a biological level, acupuncture has been associated with the release of endorphins that 
may help to minimize pain. The practice of acupuncture is complex and requires 
extensive training, thus it might be difficult for parents to find a certified acupuncturist 
who is trained to work with children. Another disadvantage is that children are likely to 
be fearful of such a technique because of the use of needles (Zeltzer & Schlank, 2005).  
Transcutaneous electrical nerve stimulation (TENS), is a physical intervention 
grounded in the Gate Control Theory. When using TENS, clinicians place electrodes on 
the skin and transmit a safe electrical currency. The currency is purported to stimulate the 
large afferent nerve fibers, which interferes with neurotransmitters and the brain’s ability 
to receive the pain signal (Sluka & Walsh, 2003). The procedure is safe and effective in 
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adults with chronic pain, and requires little preparation (Lander & Fowler-Kerry, 1993). 
Research on the effectiveness of TENS for procedural pain is mixed, and it is still unclear 
if it is helpful for children and in what capacity (Lander & Fowler-Kerry). 
Similar to TENS, physical vibration has been used to reduce pain. Concurrent 
with the Gate Control Theory vibration is believed to excite A-beta nerve fibers, which 
inhibit A-delta fiber signals, minimizing the amount of pain signal relayed to the brain 
(Pantaleo, Duranti, & Bellini, 1986; Smith, Comite, Balasubramanian, Carve, & Liu, 
2004). Small and inexpensive commercial vibrating massagers have been found to help 
reduce injection pain in adults receiving Botox® injections (Smith, Comite, 
Balasubramanian, Carver, & Liu, 2004). The authors acknowledge that some patients had 
concerns about the sexual connotation of some vibration devices. This is also likely to be 
a concern for parents of small children and adolescents. Another disadvantage is that 
some children may not like the numbing sensation created by the device. 
Additional physical techniques that have been found useful in reducing injection 
pain are pressure, stretching, and pinching at the injection site. Some studies have found 
that manual pressure prior to the injection at the site reduced pain in adults (Barnhill, 
Holbert, Jackson, & Erikson, 1996; Chung, Ng, & Wong, 2002). However, when 
applying manual pressure it is difficult to provide a consistent delivery in the amount of 
pressure. The z-track technique is an injection procedure where pressure is applied at an 
angle so that the skin is displaced prior to and during the injection. One study found that 
when using the z-track technique in adults, the immediate discomfort was higher, but 
there was less discomfort 3-4 hours later (Keen, 1986). This technique is difficult to 
standardize and might not be appropriate with children. This is also true for another 
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technique of pinching. This technique involves pinching a fold skin at the injection site. 
Fletcher (2005) found that it reduced pain in women receiving intramuscular 
contraceptive injections. 
Although the above physical interventions are viable pain management 
techniques, none of these have been validated with children. Furthermore, there are 
limitations to their use in pediatric populations, such as those mentioned above. A 
possible solution to this dilemma has been presented with the recent development of a 
physical intervention, intended especially for injection pain management in children. The 
ShotBlocker® is a u-shaped plastic device with small rounded nubs on one side that 
should be pressed against the skin at the site of the injection. The device provides a more 
consistent amount of stimulation then techniques such as pressing, pinching, or 
stretching. Theoretically, the stimulation of the nubs should send A-beta signals to the 
brain and interfere with the A-delta pain transmission of the injection. 
 Although conceptually sound, there is little data in support of the manufacturer’s 
claim that the ShotBlocker® “instantly blocks” needle pain. To date, there are four 
studies available that evaluate the ShotBlocker®, with contradictory findings. Two 
studies found that the ShotBlocker® significantly reduced children’s immunization pain 
(Guevarra, 2005; Gundrum, Sherman, & Ruhlman, 2005). The project by Gundrum et al. 
is only in a brief abstract form and reportedly submitted for publication. The study 
involved 99 patients over the age of five years, who were randomized to receive 
immunizations with or without the ShotBlocker® device. The authors report significantly 
reduced pain in the intervention group; however, specific details of method, statistics, or 
results were not provided. It appears that child self-report of pain was the exclusive 
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dependent variable with no use of observational or observer report measures. 
Communication with one of the authors, Christopher Sherman, revealed little additional 
information as this author was unable to locate a longer document or additional 
information (personal communication, November, 11, 2004) about the study. The study 
conducted by Guevarra is also in abstract form with some tables and figures to present 
the findings. This study included 119 pre-kindergarten students in the Philippines who 
were receiving intramuscular injections. Participants randomized to the treatment group 
reported significantly lower pain scores on the Wong-Baker FACES Pain Scale. Similar 
to the previous study, no measure of behavioral pain or observer report was examined. 
 Contradictory to previous finding, the remaining two studies provide some 
evidence that the ShotBlocker® may not be an effective intervention to reduce children’s 
immunization pain. Drago et al. (2007) presented a poster of their study, which included 
165 children aged 2 months to 17 years. Parents and nurses rated the child’s pain on a six 
point likert scale and children over 36 months of age provided self-report using the 
Wong-Baker FACES Pain Scale. They found that parents and nurses perceived that 
children experienced less pain when using the ShotBlocker®; however, there were no 
significant group differences in children’s self-reported pain. The fourth study is 
published in nursing research newsletter by The Children’s Hospital in Denver, Colorado 
(Foster, Eberhart, Zuk, & Finn, 2005). This research group conducted a two-group, 
randomized, controlled research study that included a diverse sample of 171 children, 
between the ages of 3 months and 17 years of age. Parents and children old enough to 
provide self-reported pain ratings, rated their pain using the Faces Pain Scale (Bieri, 
Reeve, Champion, Addicoat, & Ziegler, 1990). This study found no significant 
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differences in pain ratings between the experimental and control group (Foster, Eberhart, 
Zuk, & Finn, 2005). The contradictory findings of these studies indicate that more 
thorough evaluations of the ShotBlocker’s® effectiveness are in order.  
Summary and Purpose 
 In conclusion, despite the value of vaccinations, immunization injections cause 
multiple negative short- and long-term consequences for children. The Gate Control 
Theory of pain provides a theoretical framework to understand the complex 
multidimensional concept of pain and guides the development of pain management 
interventions (Melzack & Wall, 1965). Although physical interventions are promising, 
there are currently no validated approaches for children’s acute pain. The purpose of the 
current study is to evaluate the Shotblocker®, a new physical intervention to decrease 
injection pain in children. It is hypothesized that the ShotBlocker® condition will 
demonstrate significantly lower pain scores on child self-report, parent-report, nurse-
report, and physiological measures in comparison to typical care control and placebo 
control. An effect is anticipated in the placebo control condition, due to a reduction of the 
child’s pain expectation. Specifically, children in the placebo condition are expected to 
have lower pain on all measures of pain than children in the control condition. 
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METHOD 
Participants 
Participants included 89 parent-child dyads presenting for immunization 
injections at a southeastern pediatric practice in the Metro-Atlanta area between March, 
2006 and July, 2006. The children ranged from 4 to 12 years of age (M = 8.46 years, SD 
= 2.97 years) (Table 1). Using the effects size of 1.18 found in a prior study of the 
ShotBlocker® (Gueverra, 2005), a power analysis with power of .87 revealed that only 
12 participants would be needed to detect differences using a 3-group ANOVA. Based on 
this analysis, it was assumed that 30 participants per condition would be sufficient to find 
treatment effects. Inclusion criteria included any 4- to 12-year-old English speaking child 
receiving inoculations at the clinic. 
Fifty-two of the child participants were male (58.2%) and 76 were Caucasian 
(85.4%). Five children were African American (5.6%), one child was Asian American 
(1.1%), and seven children were reported as “mixed” or “other” by their parents (7.8%). 
Children primarily came from two-parent homes with 79 parents (88.8%) indicating they 
were married. Seven parents (7.8%) indicated they were separated or divorced and two 
parents (2.2%) reported that they were single. For most of the children, injections were 
not part of their daily routine, as only one parent (1.1%) reported the child having a 
medical condition that required routine injections, IV’s, or blood draws, and only two 
children (2.2%) were in the Neonatal Intensive Care Unit as infants. The majority of 
children were reportedly not on any pain medication (88.8%), and parents reported that 
most children were their “usual self” (75%) on the day of participation. 
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All children enrolled in the study were accompanied by either their mother (75, 
84.3%) or father (14, 15.7%). Parents ranged in age from 28 to 59 years of age (M = 40.2 
years, SD = 5.7 years); however, three parents chose not to report their date of birth. The 
parents’ years of education ranged from 12 to 23 years (M = 15.78 years, SD = 1.74 
years). The majority of families (78, 60.3%) reported annual income of $90,000 or 
greater. Twenty-two families (24.8%) reported an annual income between $30,000 and 
$89,999 and one family (1.1%) reported an annual income between $15,000 and $29,999. 
Three families chose not to report their annual income.  
Measures 
Background information 
Parents who agreed to participate in the study completed the Family Information 
Form (Appendix A), a questionnaire assessing demographics of both the child and parent, 
such as gender, age, race, and income. The parent also answered questions regarding any 
medical conditions that would require regular injections; any pain-reducing medications 
the child may have received prior to the procedure (e.g., acetaminophen); and if, when, 
and how the child was informed of receiving an injection. In addition, the parents were 
queried as to whether or not the child was born premature, and if so whether the child 
received neonatal intensive care. 
Child pain 
 Prior to the injection, children rated their baseline level of pain (Child Pre-
Injection Form, Appendix B) using the Faces Pain Scale – Revised (FPSR; Hicks, von 
Baeyer, Spafford, Korlaar, & Goodenough, 2001; Appendix C). After the injection, the 
children used the same measure to rate their pain experienced during the injection (Child 
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Post-Injection Form, Appendix D). The Faces Pain Scale – Revised (FPS-R, Appendix C) 
is a modified version of the original Faces Pain Scale (Bieri, Reeve, Champion, Addicoat, 
& Ziegler, 1990) and contains six cartoon faces expressing no pain to extreme pain. 
Children were asked to select a face that represents their level of pain prior to the 
injection and experienced pain post-injection. The six faces are coded as a pain score of 
0, 2, 4, 6, 8, or 10. Unlike other facial pain scales, the FPS-R faces are both race and 
gender neutral, both variables have been shown to bias report (Chambers & Craig, 1998). 
Another advantage of this measure is that the faces do not contain confounding 
expressions of emotion, such as tears or smiling faces, which also has been shown to 
influence self-report (Chambers & Craig). This measure is designed to create minimal 
cognitive demands on the child, thus making it appropriate for children of young ages, 
while generating scores that are comparable to other measures of pain. Research has 
shown that this measure has adequate reliability and validity (Bieri et al.; Hicks et al.).  
In addition to the children’s indication of their pain, the parents rated the pain 
their child experienced during the injection using a Visual Analog Scale (VAS) (Parent 
Post Injection Form, Appendix E). This measure consisted of a 100 mm horizontal line 
with anchor descriptors at either end of the continuum (e.g., “no pain” and “severe pain”). 
Parents were asked to draw a vertical mark on the continuum to rate their child’s pain in 
response to the question, “How much pain did your child experience during the 
injection?” This measure has been shown to be valid and reliable for both children and 
adults and is commonly used in pain research (Varni, Walco, & Wilcox 1990). After the 
injection, the nurse also rated the pain of the children using similar VAS’s (Nurse Post 
Injection Form, Appendix F). 
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Also, the children’s distress was measured with a physiological measure. A small 
electronic monitor, the Tanita® Cardio (Tanita® Corporation of America, Inc., Arlington 
Heights, IL) was used to take an electronic reading of the children’s heart rate at baseline 
and then immediately following the injection. The precision is ±5% for pulses between 
30-200 beats per minute. Each child’s change in heart rate from baseline to post injection 
served as the physiological measure of distress. 
Procedure 
 The clinical manager identified age-appropriate children who were scheduled to 
receive immunizations on days when research assistants were able to recruit participants. 
Participants were typically approached in the exam room between checking in with the 
nurse and visiting with the pediatrician. Research assistants described the study to parents 
and obtained parent consent and child assent from those interested in participating. 
With the help of the research assistant, the parent completed the Family 
Information Form (Appendix A). The research assistant provided the parent with 
instructions to complete the Visual Analog Scales and then administered the Faces Pain 
Scale-Revised (Appendices B & C) to the child. The research assistant also measured the 
baseline heart rate of both the parent and child. Once pre-measures were completed, 
participants were randomly assigned to either the typical care control (Control), the 
placebo control (Placebo), or the ShotBlocker® (ShotBlocker®) condition. The 
randomization was determined prior to the study via a random number table generated by 
the RanSL computer program (Bakeman, 1999). Once participants completed all pre-
injection measures the research assistant opened an envelope with the participant ID 
number, which had been previously generated. Inside the envelope was the participants 
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randomized condition assignment. The participants were informed that they had been 
assigned to the typical care group or one of the ShotBlocker® conditions.  
After the family had finished visiting with the pediatrician, the researcher re-
entered the exam room and set up the video camera. Before leaving the room, the 
research assistant began recording, with the video camera focused on the exam table 
where injections were administered. Video recording was done to obtain data for 
observational coding, which was not included in the analysis for the current study. The 
research assistant privately informed the nurse of the assigned condition so that the nurse 
was aware of the proper group protocol to follow. 
Typical care control 
The typical care control group received treatment as usual and the nurse was 
asked to administer the intramuscular injection without the use of the ShotBlocker®. No 
other instructions or guidance about pain management were provided to the nurse. 
Placebo control 
 Participants assigned to the placebo control group received a scripted 
introduction to the medical device (Appendix G). As was explained to the participants in 
the informed consent, they were not aware that they were assigned to the placebo control 
group. The nurse placed the ShotBlocker® on the child’s arm with the smooth side 
against the child’s skin, opposite as is prescribed by ShotBlocker®. This prevented the 
small rounded nubs from contacting the child’s skin. The purpose of this condition was to 
test for any placebo effect (e.g., child or parent expectancy the device might have in 
reducing the child’s experienced pain and anxiety). 
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ShotBlocker® 
Participants in the ShotBlocker® condition received the intervention according to 
protocol. The nurse used the same provided script as was used in the Placebo condition to 
introduce the medical device (Appendix G). Once the nurse was prepared to administer 
the injection, she/he pressed the ShotBlocker® firmly against the child’s skin at the 
injection site and held it in place while administering the injection.  
In all three conditions and immediately following the injection, the nurse obtained 
parent and child heart rate. The research assistant re-entered the exam room after the 
procedure to turn off the video camera and assist the parent and child with post-injections 
forms (Appendices C & D; Appendix E). After all forms were completed, children and 
parents who participated in the Placebo group were debriefed and told that they were part 
of the placebo control group, and then the research assistant demonstrated the correct use 
of the ShotBlocker® device with the nubby side against the skin. Participants in the 
placebo control and ShotBlocker® groups were allowed to keep their ShotBlocker® to 
use for future injections. All children received a small toy (e.g., small bouncing ball, 
pencil) to thank them for their participation. The research assistant then administered the 
post-injection VAS’s to the nurse (Appendix F).  
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RESULTS 
Participant Flow 
 This study was designed in accord with, and adheres to the guidelines detailed in 
the Consolidated Standards of Reporting Trials (CONSORT) statement (Altman et al., 
2001; Moher, Schulz, & Altman, 2001; Stinson, McGrath, & Yamada, 2003) (see Figure 
1 for the CONSORT Flowchart and Appendix H for the CONSORT Checklist). 
Appropriate institutional approval was obtained prior to initiation of data collection. On 
days when the research assistant was scheduled to collect data the clinical manager of the 
pediatric practice would identify all 4- to 12-year-olds on the schedule for the hours the 
research assistant was present. The clinical manager would then check the patients’ files 
to determine if they were likely to receive an immunization during their visit. The 
number of participants assessed for eligibility is unknown. Prior to enrollment, a number 
of families were unintentionally excluded for “other reasons,” most commonly that the 
research assistant was occupied with another participant. There were less than five cases 
when the physician requested that the patient not participate, usually because the patient 
was either too anxious or was new to the practice. There were a small number (actual 
number not recorded) of children whose parent elected not to receive the scheduled 
immunization or the child was sick and the pediatrician chose to delay the immunization. 
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Figure 1 
CONSORT Diagram Showing the Flow of 
Participants through Each Stage of a Randomized Trial 
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Data Analysis Overview 
 Preliminary analyses involved several steps. First, an examination of the 
distributions was conducted to identify outliers. Second, effectiveness of the 
randomization process was assessed by summarizing demographic characteristics of the 
entire sample and comparing demographics across conditions (Control, Placebo, 
ShotBlocker®). Third, associations between the dependent variables and demographic 
characteristics were examined. The primary analyses were conducted utilizing an 
ANCOVA to examine a main effect for treatment condition and test for a potential 
interaction between the child’s age and treatment group. 
 Some data were missing because participants did not complete all measures. In 
reports of children’s pain and anxiety, one child (1.1%) did not report their own post-
procedure pain and one parent (1.1%) failed to report their child’s procedural pain. The 
most frequently omitted procedural step was measuring the child’s heart rate, and 10 
participants (11.2%) were missing either their baseline heart rate, post-procedure heart 
rate, or both. These data were left as missing data points in analyses and other actions 
(e.g., inserting a mean value) were not taken. 
Preliminary Analysis 
Preliminary analyses were conducted for a variety of reasons. The data was first 
examined for outliers and dependent variable distributions were examined for skewness. 
Dependent variable z scores ranged from -1.50 to 2.13 indicating that there were no 
outliers. Skewness was also within normal ranges for all dependent variables, ranging 
from -.03 to .65. Next, descriptive statistics were conducted to provide information about 
the sample’s demographic characteristics and to ensure that randomization resulted in 
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equivalent groups. Analyses of variance (ANOVA) was used to compare the three 
conditions (Typical Care Control, Placebo, and ShotBlocker®) on child age and revealed 
no significant group differences (Table 1). Chi-square analyses indicated no differences 
between groups on child gender, race, history of NICU hospitalization, or existing 
medical condition that requires extra blood draws, injections, or IVs (Table 1). Thus, 
random assignment successfully balanced demographic factors across the three groups.  
 
 
Table 1  
Continuous and Categorical Demographic Variables of Entire Sample and by Condition 
  Treatment Condition  
 Entire Sample 
(n = 89) 
Control 
(n = 31) 
Placebo 
(n = 29) 
ShotBlocker® 
(n = 29) 
F (df) or X2 
(df) 
 M (SD) M (SD) M (SD) M (SD)  
Child Age (years) 8.46 (2.97) 8.33 (3.21) 8.24 (2.88) 8.80 (2.86) 0.30 (2, 86) 
Child Gender (% Male) 58.4 61.3 51.7 62.1 0.80 (2) 
Child Race (% Caucasian) 85.4 93.5 79.3 82.8 11.61 (8) 
NICU (% No) 97.7 96.8 100 96.6 0.96 (2) 
Medical Condition (% No) 98.8 100 96.3 100 2.17 (2) 
Note: No significant group differences. 
 
 
The next set of preliminary analyses examined bivariate correlations among 
demographic variables and dependent variables to determine whether considerations 
(e.g., covariates or interactions) of these variables would be needed in subsequent 
analyses. Specifically, child age was collapsed across conditions and, as expected, results 
revealed significant negative correlations between child’s age and all ratings of child pain 
and anxiety (e.g., child-, caregiver-, and health care provider-report) (Table 2). Child, 
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parent, and healthcare provided reports of the child’s pain and anxiety were all 
significantly negatively correlated with the child’s age, indicating that younger children 
experienced more procedural distress. The physiological measure of the child’s heart rate 
change was not significantly correlated with the child’s age. 
 
 
Table 2 
Bivariate correlations of Child Age with Dependent Variables  
 Child Age 
Child Pain  
     Self-report -.58** 
     Parent-report -.53** 
     HCP-report  -.47** 
     Heart-Rate Change -.04 
Child Anxiety  
     Parent-report -.41** 
     HCP-report -.39** 
** p<.01 
 
 
Ethnicity and gender were examined with ANOVA procedures to determine 
whether child distress differed on these variables. None of the outcome variables were 
significantly different across child gender or ethnicity. Only one child indicated having a 
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medical condition that required extra procedures and only two children reported NICU 
care at birth. Because of the low frequency, the dependent variables for these specific 
participants were analyzed and none of the data points were outliers relative to the sample 
(i.e., all z scores for dependent variables were less than 2).  
Primary Analyses 
An Analysis of Variance (ANCOVA) was used to examine the main effect of 
treatment condition, while controlling for the child’s age and also tested for a potential 
interaction between treatment condition and child age. Child age continued to predict 
child pain and anxiety on each dependent variable, except the physiological measure of 
change in child heart rate; however, treatment condition was not significant for any of the 
dependent variables, nor were there any significant interactions (see Table 3). 
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Table 3 
ANCOVA Analysis for Treatment Effects with Age as Covariate and Age x Condition 
Interaction 
 Factors F Partial eta2 
Child Heart Rate Change Child Age  .21   .00 
 Condition 1.08   .03 
 Age x Condition 1.50   .04 
    
Child Pain    
     Self-report Child Age 39.41** .36 
 Condition .32 .01 
 Age x Condition .42 .01 
      
     Caregiver-report 
 
Child Age 
 
36.24**
 
.31 
 Condition 1.78 .04 
 Age x Condition 2.21 .05 
      
     HCP-report  
 
Child Age 
 
24.87**
 
.23 
 Condition .64 .02 
 Age x Condition .37 .01 
    
Child Anxiety    
     Caregiver-report Child Age 17.92** .18 
 Condition .26 .01 
 Age x Condition .12 .00 
      
     HCP-report 
 
Child Age 
 
14.85**
 
.15 
 Condition .58 .01 
 Age x Condition .86 .02 
** p<.01 
 
 
28 
DISCUSSION 
Effectiveness of ShotBlocker® 
 This study evaluated the ShotBlocker®, a new physical intervention to decrease 
injection pain in children. The hypotheses of the current study were not supported in that 
the results revealed no significant differences in child pain and anxiety as reported by 
children, their parents, healthcare providers, or heart rate across the ShotBlocker®, 
Placebo, or Typical Care conditions.  
 The Gate Control Theory of Pain suggests that the ShotBlocker® should interfere 
with the ascending pain signal; however, results did not support the hypothesis. It is 
important to acknowledge that the theory has never been definitively proven and may be 
an oversimplification of the complex construct of pain. It may simply not have 
application in a physical intervention to reduce children’s immunization pain. It is also 
possible that the theory is partially accurate in that the pain signals travel through a gating 
mechanism in route to the brain; however, the Gate Control Theory does not discuss the 
strength of ascending versus descending signals. In other words, it is possible that the 
physical intervention does provide a competing ascending signal to the brain, but that the 
descending cognitive/emotional factors, such as negative expectations or pre-procedural 
anxiety, override any interference caused by the physical intervention. In the context of 
an immunization, a child’s anxiety may open the gate and negate the effectiveness of a 
physical intervention such as the ShotBlocker®. 
Previous research evaluating the ShotBlocker® is limited, and found mixed 
support regarding the effectiveness of the device in reducing children’s immunization 
pain (Drago et al., 2007; Foster, Eberhart, Zuk, & Finn, 2005; Guevarra, 2005; Gundrum 
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et al., 2005). Two of the studies found that the ShotBlocker® was an effective 
intervention in reducing children’s immunization pain. One possible explanation for the 
discrepancy between these findings with the current study is the potential differences in 
methodology. Given that they are only poster presentations and there are no detailed 
reports, little is known about the methodology of these two prior studies. For example, 
the two previous studies did not include a placebo control group. Thus, if children were 
provided extensive information about the device or there were other variables present in 
the treatment condition, the findings may have simply been due to a placebo effect. In 
comparison, the current study included a placebo condition and also controlled and 
limited the information that the healthcare professionals provided to the participants 
about the device. It is also not clear how participants were assigned or randomized to 
treatment group and there may have been a sampling bias in the previous studies. 
Another possible explanation for the discrepancy in findings is that the sample in 
this study was significantly different demographically from previous studies, which may 
have impacted the results. For example, the study by Guevarra (2005) was collected in 
the Philippines and cultural differences may have played a role in the effectiveness of the 
ShotBlocker®. Demographic information for the study conducted by Gundrum et al., 
(2005) was not available for comparison. 
The study by Drage et al. (2007) found that parents and nurses perceived lower 
needle pain for children in the ShotBlocker® group than the control group, but there were 
no significant differences in children’s self-reported pain. This might have been the result 
of a placebo effect for nurses and parents. Similar to the findings of the current study, 
Foster, Eberhart, Zuk, and Finn (2005) found no significant differences in parent, nurse, 
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or child self-report pain ratings between the ShotBlocker® condition and the control 
group. Thus, there are corroborating data to suggest that the ShotBlocker® is not an 
effective pediatric pain management intervention. 
Limitations and Future Directions 
There are several limitations to the current study that should be noted. The sample 
was primarily upper class, with more than half the sample reporting a family income 
greater than $90,000 annually. The sample was also mostly Caucasian. Although a 
homogeneous sample such as this one increased internal validity, it raises questions 
regarding the generalizability of these findings to children of different ethnicities and 
lower social economical classes. This is especially pertinent given discrepancies in these 
findings and those with a sample from the Philippines (Guevarra, 2005). 
The setting for the study, a group practice pediatric office, had its advantages and 
disadvantages. For example, given that this was a busy pediatric practice, the staff might 
have hurried through the explanation of the device to the participants, which may have 
neutralized any potential placebo effect. On the other hand, the medical setting provided 
a realistic evaluation of the ShotBlocker®’s effectiveness in a real-life setting.  
Finally, the current study may not have adequately assessed the child’s pain 
response to the injection because it relied too heavily on the subjective ratings from the 
child, parent, and healthcare provider. Subjective ratings of pain might not be as objective 
as behavioral observation measures. One reason subjective ratings may be less accurate is 
that research is has found the ratings are influenced by different factors. For example, 
Manne et al. (1992) found that caregiver ratings were a more accurate reflection of their 
own anxiety and healthcare providers were found to rate the child based on overt 
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behavioral distress and using past experiences with other children. Further supporting this 
argument, previous research has found significant treatment effects of distraction for 
pediatric pain management with an observational measure when there were no significant 
differences among caregiver and health care provider ratings (Cohen, 2002).  
Additionally, subjective ratings are limited, in that they reflect a global evaluation 
of a complex procedural experience. For example, children, parents, and caregivers, may 
base their ratings on specific parts of the procedure, such as anxiety related to the 
injection, or immediate reaction to the painful stimulus itself, as opposed to how quickly 
the child recovered from the pain and anxiety in the minutes after the needle has been 
removed (e.g. Cohen, 2002; Cohen et al., 2006). Observational coding typically measures 
distress during different phases of a medical procedure and may have been able to 
identify differences in levels of distress by treatment group if they were present.  
The lack of observational data limits the findings, particularly in terms of 
understanding children’s distress during different phases of the procedure, such as 
anticipatory and recovery. Observational data was collected as part of this study and will 
be analyzed in the future to help further evaluate the effectiveness of the ShotBlocker®. 
Future studies should continue to examine the effectiveness of physical 
interventions in reducing children’s procedural pain. Additional exploration of factors 
(e.g. child’s anticipatory anxiety, verbal explanation of physical intervention) that may 
facilitate physical interventions should also be explored. 
Conclusions 
 The current study did not support the ShotBlocker® as an effective intervention to 
reduce children’s pain during immunization injections. Despite the lack of significant 
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findings, the current study contributes to the literature on the Gate Control Theory of 
Pain. The current study provided additional evidence that younger children experience 
higher injection distress and might be in greater need for pain reduction interventions. As 
immunization injections are a common procedure for children and the distress children 
experience has both short- and long- term consequences, it is important for researchers to 
continue evaluating and advocating for the implementation of effective pain management 
interventions. On balance, it is also important that research reveal when interventions are 
not effective lest practitioners spend time, money, and energy with interventions that do 
not provide benefit to the patient. 
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Family Information Form 
 
 
Please take a moment to complete the following forms. If you have any questions, 
please ask. Thanks! 
 
1. Your Relation to Child:  ___Mother  ___Father  ___Grandparent  If other, 
describe: ____ 
 
2. Your Gender:   ___Male  ___Female  
 
3. Your Date of Birth:  ____/_____/_____ 
  
4. Are you Latino?   ___Yes  ___No 
 
5. Your Race:   ___White  ___Black  ___Asian/Pacific Islander  ___Mixed 
If other, describe: ___________ 
 
6. How many years of school have you completed?   ___ 
 
7. Your Marital Status: ___Single  ___Married  ___Separated  ___Divorced  
___Widowed 
 
8. How many years of school has your spouse/partner completed?   ___ 
 
9. Approximate total family income per year: ?Less than $14,999   ?$15,000-
$29,999   ?$30,000-$59,999   ?$60,000-$89,999   ?$90,000 or more 
 
10. Child’s Gender:  ___Male  ___Female 
 
11. Child’s Date of Birth:  ____/____/____ 
 
12. Is your child Latino?   ___Yes  ___No 
 
13. Your child’s race:   ___White  ___Black  ___Asian/Pacific Islander  
___Mixed 
If other, describe: ___________ 
 
14. Was your child born premature? ____ Yes     _____ No 
If Yes, was your child in the NICU (Neonatal Intensive Care Unit?)  ____Yes     
____No 
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15. What, if any pain medication has your child received today (e.g., Tylenol)? 
___________ 
 
16. Is this child his/her usual self today? If not, Why?  
______________________________ 
 
17. Did you tell your child that they will be getting a shot today?  ____ Yes
 ____ No 
If Yes, when did you tell them? __________________________ 
 
18. Does your child have a medical condition requiring extra blood 
draws/injections/IVs? If so, what is the condition?  ___________ 
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Child Pre-Injection Form (FPS-R) 
 
 
For Researcher Use 
 
Show the child the Faces Pain Scale - Revised. Point to the row of faces. 
 
Say: 
 
 
These faces show how much pain a child can feel. This face (point to the left-most 
face) shows no pain. The faces show more and more pain (point to each from left to 
right) up until this one (point to the right-most face) it shows very much pain. 
 
 
1. Point to the face that shows how much pain you will feel right now 
 
  Child’s response:  Face # _________________ 
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Child Post-Injection Form (FPS-R) 
 
 
For Researcher Use 
 
Show the child the Faces Pain Scale - Revised. Point to the row of faces. 
 
Say: 
 
 
Remember these faces? They show how much pain a child can feel. This face (point 
to the left-most face) shows no pain. The faces show more and more pain (point to 
each from left to right) up until this one (point to the right-most face) it shows very 
much pain. 
 
 
2. Point to the face that shows how much pain you felt during the injection 
 
  Child’s response:  Face # _________________ 
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Parent Post-Injection Form 
 
 
 
Please answer the following questions using the lines in the same way you did 
on the last form. If you have any questions, feel free to ask. 
  
1. How Anxious were you during your child’s injection? 
 
Not Anxious          Very 
Anxious  
 
 
2. How Anxious was your child during the injection? 
 
Not Anxious          Very 
Anxious 
 
 
3. How much Pain did your child experience during the injection? 
 
No Pain          Severe 
Pain 
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Nurse Post-Injection Form 
 
 
 
Please answer the following questions using the lines below. Please put a mark 
so that it intersects the line. If you have any questions, feel free to ask. 
 1. How Anxious was this parent during this child’s injection? 
 
Not Anxious          Very 
Anxious 
 
 
2. How Anxious was this child during the injection? 
 
Not Anxious          Very 
Anxious 
 
 
3. How much Pain did this child experience during the injection? 
 
No Pain          Severe 
Pain 
 
 
4. How Anxious were you during this child’s injection? 
 
Not Anxious          Very 
Anxious 
 
5. Parent heart rate _____/minute (immediately following the injection) 
 
6. Child heart rate _____/minute (immediately following the injection) 
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Nurse Script - Introduction of ShotBlocker® 
 
Nurse is to use the following script to introduce the medical device 
to both the treatment group and placebo control group. 
 
(Show child device). This is called the ShotBlocker. It is used to help make shots hurt 
less. I am going to hold it against your arm like this (nurse demonstrates on own arm*) 
while I give you your shot. It doesn’t hurt at all. Would you like to hold it and see what it 
feels like? Now I will show you how it feels on your arm (nurse demonstrates on child’s 
arm*). 
*If child is in the ShotBlocker® group, press the device with nubs against skin. If child is 
in Placebo control, press the device with smooth side against the skin. 
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PAPER SECTION 
And topic 
Item Description Reported on 
Page # 
TITLE & 
ABSTRACT 
1 How participants were allocated to 
interventions (e.g., "random allocation", 
"randomized", or "randomly assigned"). 
 
i 
INTRODUCTION 
Background 
2 Scientific background and explanation of 
rationale. 
 
1 
METHODS 
Participants 
3 Eligibility criteria for participants and the 
settings and locations where the data were 
collected. 
 
14 
Interventions 4 Precise details of the interventions intended 
for each group and how and when they 
were actually administered. 
 
18 
Objectives 5 Specific objectives and hypotheses. 13 
Outcomes 6 Clearly defined primary and secondary 
outcome measures and, when applicable, 
any methods used to enhance the quality of 
measurements (e.g., multiple observations, 
training of assessors). 
 
 
 
15 
Sample size 7 How sample size was determined and, 
when applicable, explanation of any interim 
analyses and stopping rules. 
 
14 
Randomization -- 
Sequence 
generation 
8 Method used to generate the random 
allocation sequence, including details of any 
restrictions (e.g., blocking, stratification) 
 
 
17 
Randomization -- 
Allocation 
concealment 
9 Method used to implement the random 
allocation sequence (e.g., numbered 
containers or central telephone), clarifying 
whether the sequence was concealed until 
interventions were assigned. 
 
 
 
17 
Randomization -- 
Implementation 
10 Who generated the allocation sequence, 
who enrolled participants, and who 
assigned participants to their groups. 
 
 
 
Blinding (masking) 11 Whether or not participants, those 
administering the interventions, and those 
assessing the outcomes were blinded to 
group assignment. When relevant, how the 
success of blinding was evaluated. 
 
 
 
17 
Statistical 
methods 
12 Statistical methods used to compare groups 
for primary outcome(s); Methods for 
additional analyses, such as subgroup 
analyses and adjusted analyses. 
 
 
26 
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RESULTS 
Participant flow 
 
13 Flow of participants through each stage (a 
diagram is strongly recommended). 
Specifically, for each group report the 
numbers of participants randomly assigned, 
receiving intended treatment, completing 
the study protocol, and analyzed for the 
primary outcome. Describe protocol 
deviations from study as planned, together 
with reasons. 
 
 
 
 
 
22 
Recruitment 14 Dates defining the periods of recruitment 
and follow-up. 
14 
Baseline data 15 Baseline demographic and clinical 
characteristics of each group. 
24 
Numbers 
analyzed 
16 Number of participants (denominator) in 
each group included in each analysis and 
whether the analysis was by "intention-to-
treat".   State the results in absolute 
numbers when feasible (e.g., 10/20, not 
50%). 
 
 
 
24 
Outcomes and 
estimation 
17 For each primary and secondary outcome, 
a summary of results for each group, and 
the estimated effect size and its precision 
(e.g., 95% confidence interval). 
 
 
27 
Ancillary analyses 18 Address multiplicity by reporting any other 
analyses performed, including subgroup 
analyses and adjusted analyses, indicating 
those pre-specified and those exploratory. 
 
 
 
26 
Adverse events 19 All important adverse events or side effects 
in each intervention group. 
 
N/A 
DISCUSSION 
Interpretation 
20 Interpretation of the results, taking into 
account study hypotheses, sources of 
potential bias or imprecision and the 
dangers associated with multiplicity of 
analyses and outcomes. 
 
 
 
28 
Generalizability 21 Generalizability (external validity) of the trial 
findings. 
28 
Overall evidence 22 General interpretation of the results in the 
context of current evidence. 
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